Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman.
The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn, vice president of professional and specialty development; Ed Shupenus, executive director of marketing operations; and Steve Kreider, executive director of sales and marketing for SILIQ™ (brodalumab) injection, for subcutaneous use.
In their new roles, Mr. McMyne and Ms. Williams will be responsible for the sales and marketing strategy and execution of the organization, respectively. Mr. McMyne most recently served as vice president of operations for Merz North America, Inc., a specialty pharmaceutical and medical device company focused on dermatology, aesthetics medicine and neurosciences. While at Merz, Mr. McMyne launched a channel marketing team and led the integration of two key acquisitions by the company, Neocutis and Ulthera. Prior to joining Merz, Mr. McMyne served in various commercial roles at Medicis Pharmaceuticals, including associate director of sales for dermatology.
Ms. Williams has diverse experience in commercial healthcare that includes medical devices, pharmaceuticals, R&D, and manufacturing. Prior to this new role, she was senior marketing director for Merz North America, where she led strategic direction and tactical execution for a neuroscience portfolio that included biologic, pharmaceutical and medical device products.
Responsible for the upcoming launch of SILIQ, Mr. Kreider has extensive experience in marketing, including having led all aspects of marketing for Merz North America’s Ulthera business. Mr. Kreider joined Merz as director of business development, culminating with the commercial integration of Ulthera into Merz. Prior to Merz, he held sales and marketing leadership roles of increasing responsibility at Medicis, and later Valeant after its 2012 acquisition of the company.
Mr. Shupenus and Mr. Hahn have both received promotions to their new roles, reflecting their deep physician relationships and long-time involvement in the industry. Mr. Hahn joined Valeant in 2011 as director, professional relations for Valeant Dermatology. Previously, he worked at Ortho Dermatologics, a division of Johnson & Johnson, holding increasing positions of responsibility, including director of professional relations, where he oversaw key opinion leader programs for both general and aesthetic dermatology.
Mr. Shupenus came to Valeant from Ortho Dermatologics, where he was the global group product director overseeing marketing for a dermatology portfolio, which increased net sales every year. Mr. Shupenus was also responsible for commercial business development, the company pipeline, alternate-selling channels and co-promotion agreements, including promotion of Stelara in psoriasis and Ertaczo in podiatry.